Cranberry Research Today is a free monthly online journal that collates and summarizes the latest research about Cranberry, including details on benefits, antioxidants, utis, cystitis.

Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice.

Lee SD, Lee SJ, Hwang TK, Yoon DK, Lee KS, Sung LH, Choo MS, Shim BS, Cho IR, Kim ME, Ryu SB, Kim CS, Kim YG, Kim CI, Rhew HY, Kim MH, Cho YH

Department of Urology, Pusan National University Hospital, 1-10 Ami-dong, Seo-gu, Busan, South Korea; Korean Association of Urogenital Tract Infection, South Korea.

To investigate the efficacy and safety of gatifloxacin (400mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N=149, mean 45.8+/-13.3 years) and cystitis (N=304, mean 53.8+/-14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis.

Published 8 August 2006 in Int J Antimicrob Agents, 28: 108-12.
Full-text of this article is available online (may require subscription).

© 2004-2008 Cranberry Research Today. All Rights Reserved.